信函：雷帕霉素机制性靶点抑制剂作为肝移植肝细胞癌患者辅助治疗的研究 - Suppr | 超能文献

Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation.

作者信息

Rodríguez-Perálvarez Manuel, Amado Victor, de la Mata Manuel

机构信息

Department of Hepatology and Liver Transplantation, IMIBIC, CIBERehd, Reina Sofía University Hospital, Córdoba, Spain.

出版信息

Aliment Pharmacol Ther. 2019 Aug;50(4):478-479. doi: 10.1111/apt.15300.

DOI:10.1111/apt.15300

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation.信函：雷帕霉素机制性靶点抑制剂作为肝移植肝细胞癌患者辅助治疗的研究

Aliment Pharmacol Ther. 2019 Aug;50(4):478-479. doi: 10.1111/apt.15300.

2

Letter: mechanistic target of rapamycin inhibitors-do they impact on recurrence of hepatocellular carcinoma after liver transplantation?信件：雷帕霉素作用机制抑制剂——它们对肝移植后肝细胞癌复发有影响吗？

Aliment Pharmacol Ther. 2019 Jul;50(1):116-117. doi: 10.1111/apt.15310.

3

Letter: mechanistic target of rapamycin inhibitors-do they impact on recurrence of hepatocellular carcinoma after liver transplantation? Authors' reply.信函：雷帕霉素作用机制抑制剂——它们对肝移植后肝细胞癌复发有影响吗？作者回复。

Aliment Pharmacol Ther. 2019 Jul;50(1):117-120. doi: 10.1111/apt.15324.

4

Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.雷帕霉素哺乳动物靶点抑制剂与肝移植后肝细胞癌复发率较低相关：一项系统评价

Transpl Int. 2014 Oct;27(10):1039-49. doi: 10.1111/tri.12372. Epub 2014 Jul 18.

5

Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.肝移植后复发风险高的肝细胞癌患者基于依维莫司的免疫抑制：病例系列

Transplant Proc. 2014 Dec;46(10):3496-501. doi: 10.1016/j.transproceed.2014.08.045.

6

Use of everolimus in liver transplantation: The French experience.依维莫司在肝移植中的应用：法国的经验。

Transplant Rev (Orlando). 2016 Jul;30(3):161-70. doi: 10.1016/j.trre.2015.12.003. Epub 2016 Mar 18.

7

Mammalian Target of Rapamycin Inhibitors Against Hepatocellular Carcinoma Recurrence After Liver Transplantation.雷帕霉素哺乳动物靶点抑制剂用于预防肝移植后肝细胞癌复发

Transplantation. 2016 Aug;100(8):e43-4. doi: 10.1097/TP.0000000000001256.

8

mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.mTOR抑制剂和索拉非尼用于原位肝移植后复发性肝细胞癌

J Hepatol. 2011 Feb;54(2):396-8. doi: 10.1016/j.jhep.2010.08.038. Epub 2010 Nov 10.

9

Letter: the effect of sirolimus on recurrence and survival in liver transplant recipients with hepatocellular carcinoma.信函：西罗莫司对肝细胞癌肝移植受者复发及生存的影响

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1330-1331. doi: 10.1111/apt.14963.

10

Letter: the effect of sirolimus on recurrence and survival in liver transplant recipients with hepatocellular carcinoma-authors' reply.信函：西罗莫司对肝细胞癌肝移植受者复发和生存的影响——作者回复

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1331-1332. doi: 10.1111/apt.15038.

引用本文的文献

1

Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.mTOR 信号通路在肝细胞癌中的激活。

Int J Mol Sci. 2020 Feb 13;21(4):1266. doi: 10.3390/ijms21041266.